-
Archives
- June 2018
- February 2018
- May 2017
- January 2017
- December 2016
- November 2016
- October 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- August 2015
- July 2015
- June 2015
- March 2015
- February 2015
- September 2014
- July 2014
- January 2014
- November 2013
- July 2013
- June 2013
- April 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- June 2012
- May 2012
- March 2012
- December 2011
- November 2011
- July 2011
- March 2011
-
Meta
Tag Archives: TQT
Cardiac Safety – the regulatory perspective
Dr Krishna Prasad, MHRA Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). Krishna reviewed the status quo pointing out that the regulations were a success in that no drugs having undergone E14 … Continue reading
Comments Off on Cardiac Safety – the regulatory perspective
Cardiac Safety – the industry perspective
Dr Boaz Mendzelevski, BioClinica Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). This year marks the 10th anniversary of the introduction of the ICH E14 guideline which was introduced to provide … Continue reading
Comments Off on Cardiac Safety – the industry perspective
Faculty conversation: TQT study – this is the end!
Recently, the FDA, other regulatory bodies, and pharmaceutical companies have been exploring options to replace TQTs with preclinical testing or with data collected during standard Phase I trials. Join colleagues from the FPM and also the British Pharmacological Society and … Continue reading
Comments Off on Faculty conversation: TQT study – this is the end!